Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma

Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma

Cecilia Monge,1 Changqing Xie,1 Seth M Steinberg,2 Tim F Greten1,3 1Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA; 2Biostatistics and Data Management Section,...

Full description

Bibliographic Details
Main Authors: Monge C, Xie C, Steinberg SM, Greten TF
Format: Article
Language:English
Published: Dove Medical Press 2021-05-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
hepatocellular carcinoma
immunotherapy
long term overall survival
immune related adverse events
tremelimumab
durvalumab
Online Access:https://www.dovepress.com/clinical-indicators-for-long-term-survival-with-immune-checkpoint-ther-peer-reviewed-fulltext-article-JHC

Internet

https://www.dovepress.com/clinical-indicators-for-long-term-survival-with-immune-checkpoint-ther-peer-reviewed-fulltext-article-JHC

Similar Items